← Back to all signals
RESEARCH PAPER ANALYSIS

Trends in rehabilitation needs for neurological disorders in China, 1990-2021: a cross-sectional analysis of the Global Burden of Disease Study 2021.

Using Global Burden of Disease 1990–2021 data the study quantifies rising prevalence and YLDs for 10 neurological disorders in China—particularly stroke, Alzheimer's, and a rapidly increasing Parkinson's disease burden—and forecasts continued growth to 2050 with major rehabilitation and geographic…

PMID42040541
JournalFrontiers in medicine
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Using Global Burden of Disease 1990–2021 data the study quantifies rising prevalence and YLDs for 10 neurological disorders in China—particularly stroke, Alzheimer's, and a rapidly increasing Parkinson's disease burden—and forecasts continued growth to 2050 with major rehabilitation and geographic…

WHY IT MATTERS

Research significance

Valuable for health-policy and care-planning by documenting a growing Parkinson's rehabilitation burden in China, but it provides little mechanistic insight or direct therapeutic targets for drug discovery.

ABSTRACT

Source abstract

BACKGROUND: Neurological disorders are a leading cause of long-term disability, generating substantial rehabilitation needs. China's rapid population aging and evolving epidemiological profile underscore the urgency of quantifying these needs. METHOD: Using data from the Global Burden of Disease Study 2021, we assessed rehabilitation needs for 10 neurological disorders in China from 1990 to 2021. Prevalence and years lived with disability (YLDs) were analyzed by age, sex, and cause, benchmarked against global trends. Temporal trends were quantified by estimated annual percentage change (EAPC), and Bayesian age-period-cohort modeling was applied to forecast to 2050. RESULTS: From 1990 to 2021, China's age-standardized prevalence and YLDs rates increased significantly, with EAPCs of 0.42 (95% CI 0.38 to 0.45) and 0.40 (95% CI 0.36 to 0.43), both exceeding global averages. The largest absolute burdens in 2021 were from stroke, Alzheimer's disease, and Parkinson's disease. Parkinson's disease (EAPC = 1.85, 95% CI 1.78 to 1.92), multiple sclerosis (1.42, 95% CI 1.36 to 1.48), and motor neuron disease (1.11, 95% CI 1.05 to 1.17) showed the steepest proportional rises. Women bore higher late-life burdens, while men had greater trauma-related disability. Rehabilitation needs were concentrated in older adults, with substantial geographic and service-access inequities reported in prior national surveys. Forecasts to 2050 indicate sustained growth, with neurodegenerative disorders comprising an increasing share of total rehabilitation demand. CONCLUSION: The scale and pace of growth in China's neurological rehabilitation needs reflect demographic aging, improved survival, and persistent service gaps. Meeting this challenge will require decentralizing rehabilitation, integrating disease-specific pathways into universal health coverage, and prioritizing underserved rural and older populations.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic